Related Experiment Video

Updated: May 9, 2026

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

[Delay in the introduction of treatment modalities for neuroendocrine tumors in Japan]

Masayuki Imamura1

  • 1Kansai Electric Power Hospital, Endocrine Tumor Center, Osaka, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|July 19, 2013
PubMed

Insights

The global incidence of pancreatic-intestinal neuroendocrine tumors is rising, necessitating standardized treatments. In Japan, key diagnostic tools like somatostatin receptor scintigraphy (SRS) lack government approval, hindering optimal patient care.

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Gastroenterology

Context:

  • Pancreatic-intestinal neuroendocrine tumors (NETs) represent a growing global health concern.
  • Standardization of diagnostic and treatment protocols for NETs is an ongoing challenge.
  • Specific diagnostic modalities, such as somatostatin receptor scintigraphy (SRS), face regulatory hurdles in Japan.

Purpose:

  • To address the unmet need for approved diagnostic and treatment modalities for pancreatic-intestinal neuroendocrine tumors in Japan.
  • To advocate for the integration of advanced imaging techniques like SRS into routine clinical practice.
  • To improve the management and outcomes for patients with neuroendocrine tumors in Japan.

Summary:

  • The incidence of pancreatic-intestinal neuroendocrine tumors (NETs) is increasing worldwide.
  • Intensive research focuses on standardizing NET treatment protocols.
  • Key diagnostic tools, including somatostatin receptor scintigraphy (SRS), are not government-approved in Japan, creating a treatment gap.

Impact:

  • This initiative aims to expedite the approval of essential diagnostic and treatment tools for NETs in Japan.
  • Improved access to modalities like SRS will enhance diagnostic accuracy and treatment planning.
  • Ultimately, this will lead to better patient care and outcomes for individuals with neuroendocrine tumors in Japan.

More Related Videos

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Cushing Syndrome I: Introduction01:26

Cushing Syndrome I: Introduction

Cushing syndrome refers to the collection of clinical manifestations that arise when tissues are exposed to excessive amounts of cortisol or cortisol-like medications over an extended period. Cortisol, a glucocorticoid produced by the adrenal cortex, regulates metabolism, immune responses, and the body’s adaptation to stress. When its concentration remains chronically elevated, these physiological pathways become dysregulated, resulting in the characteristic features of the syndrome.Exogenous...